CETX Cemtrex Receives over $20M in New Orders in i
Post# of 42389
Farmingdale, NY – July 23, 2018 – Cemtrex Inc. (Nasdaq: CETX, CETXP, CETXW), a world leading technology and manufacturing company, announced today that the company received over $20 million in new orders in its Electronics Manufacturing Services (EMS) Segment during its most recent quarter ended June 30th, 2018.
The Company’s new orders were driven primarily by customers in medical devices, industrial technology, automation, and measurement devices. The orders came from both new customers and existing customers such as ERBE, Stäubli, and Heinzmann. These new orders bring the total EMS segment’s backlog up to over $50M in total which puts the segment on a path toward organic growth of 10% over the next twelve months.
Cemtrex’s Chairman and CEO, Saagar Govil, commented, “We are encouraged with the recent success of our EMS segment. We have been able to rebound from a decline in sales last quarter with these new bookings. With $50M in backlog this gives us a strong foundation for us to continue growing within this segment.”
About Cemtrex
Cemtrex, Inc. (NASDAQ:CETX) is the manufacturer of the SmartDesk, the world’s most advanced workstation. Cemtrex is a diversified technology company that’s driving innovation in a wide range of sectors, including smart technology, virtual and augmented realities, advanced electronic systems, industrial solutions, and intelligent security systems.
www.cemtrex.com
1️⃣I do not provide personal investment advice and I am not a qualified licensed investment advisor. I am an amateur investor.
2️⃣All information found here, including any ideas, opinions, views, predictions, forecasts, commentaries, suggestions, or stock picks, expressed or implied herein, are for informational, entertainment or educational purposes only and should not be construed as personal investment advice. While the information provided is believed to be accurate, it may include errors or inaccuracies.
3️⃣I will not and cannot be held liable for any actions you take as a result of anything you read here.
4️⃣Conduct your own due diligence, or consult a licensed financial advisor or broker before making any and all investment decisions. Any investments, trades, speculations, or decisions made on the basis of any information found on this site, expressed or implied herein, are committed at your own risk, financial or otherwise.